Trial Profile
International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms SALUS
- Sponsors Advanced Accelerator Applications
- 07 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2022 Planned number of patients changed from 900 to 1000.
- 30 Jun 2022 Status changed from suspended to recruiting, according to a Novartis media release.